• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

实验性暴露于中和血清诱导 SARS-CoV-2 主要谱系中的突变。

Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera.

机构信息

Unit of Microbiology, The Greater Romagna Area Hub Laboratory, 47522, Cesena, Italy.

Department of Experimental, Diagnostic and Specialty Medicine (DIMES)-Alma Mater Studiorum, University of Bologna, 40138, Bologna, Italy.

出版信息

Sci Rep. 2022 Jul 21;12(1):12479. doi: 10.1038/s41598-022-16533-4.

DOI:10.1038/s41598-022-16533-4
PMID:35864211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9302871/
Abstract

The ongoing evolution of SARS-CoV-2 and the emergence of new viral variants bearing specific escape mutations responsible for immune evasion from antibody neutralisation has required a more accurate characterisation of the immune response as one of the evolutive forces behind viral adaptation to a largely immunised human population. In this work, culturing in the presence of neutralising sera vigorously promoted mutagenesis leading to the acquisition of known escape mutations on the spike as well as new presumptive escape mutations on structural proteins whose role as target of the neutralizing antibody response might have been thus far widely neglected. From this perspective, this study, in addition to tracing the past evolution of the species back to interactions with neutralising antibody immune response, also offers a glimpse into future evolutive scenarios.

摘要

SARS-CoV-2 的持续进化以及出现新的病毒变种,这些变种带有特定的逃逸突变,能够逃避抗体中和作用,这使得我们需要更准确地描述免疫反应,将其视为病毒适应大部分免疫人群的进化力量之一。在这项工作中,在存在中和血清的情况下培养有力地促进了突变,导致刺突上获得已知的逃逸突变,以及结构蛋白上的新假定逃逸突变,这些突变的作用作为中和抗体反应的靶标可能迄今为止被广泛忽视。从这个角度来看,这项研究除了追溯该物种的过去进化,追溯到与中和抗体免疫反应的相互作用,还提供了对未来进化场景的一瞥。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be45/9304374/05658fe186ba/41598_2022_16533_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be45/9304374/b019c9a8a1ad/41598_2022_16533_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be45/9304374/05658fe186ba/41598_2022_16533_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be45/9304374/b019c9a8a1ad/41598_2022_16533_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/be45/9304374/05658fe186ba/41598_2022_16533_Fig2_HTML.jpg

相似文献

1
Mutational induction in SARS-CoV-2 major lineages by experimental exposure to neutralising sera.实验性暴露于中和血清诱导 SARS-CoV-2 主要谱系中的突变。
Sci Rep. 2022 Jul 21;12(1):12479. doi: 10.1038/s41598-022-16533-4.
2
Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.两种带有刺突蛋白突变的 SARS-CoV-2 变异株对中和抗体的敏感性。
Virus Genes. 2021 Dec;57(6):502-509. doi: 10.1007/s11262-021-01871-8. Epub 2021 Oct 4.
3
Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants.全面绘制 SARS-CoV-2 RBD 特异性中和抗体的结合热点,用于跟踪免疫逃逸变异株。
Genome Med. 2021 Oct 14;13(1):164. doi: 10.1186/s13073-021-00985-w.
4
SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.SARS-CoV-2 从高中和性的 COVID-19 恢复期血浆中逃逸。
Proc Natl Acad Sci U S A. 2021 Sep 7;118(36). doi: 10.1073/pnas.2103154118.
5
Evolutionary and Phenotypic Characterization of Two Spike Mutations in European Lineage 20E of SARS-CoV-2.两种 SARS-CoV-2 欧洲谱系 20E 刺突突变的进化和表型特征。
mBio. 2021 Dec 21;12(6):e0231521. doi: 10.1128/mBio.02315-21. Epub 2021 Nov 16.
6
Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD.SARS-CoV-2 逃逸突变体对靶向 RBD 和 NTD 的一对中和抗体的鉴定。
Int J Mol Sci. 2022 Jul 25;23(15):8177. doi: 10.3390/ijms23158177.
7
Mutational Hotspot in the SARS-CoV-2 Spike Protein N-Terminal Domain Conferring Immune Escape Potential.SARS-CoV-2 刺突蛋白 N 端结构域中的突变热点赋予免疫逃逸潜能。
Viruses. 2021 Oct 20;13(11):2114. doi: 10.3390/v13112114.
8
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants.靶向 SARS-CoV-2 刺突蛋白的治疗性中和抗体的综合工程改造以中和逃逸变异株。
MAbs. 2022 Jan-Dec;14(1):2040350. doi: 10.1080/19420862.2022.2040350.
9
The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum.刺突 N501Y 突变对 SARS-CoV-2 恢复期血清中和活性和 RBD 结合的影响。
EBioMedicine. 2021 Sep;71:103544. doi: 10.1016/j.ebiom.2021.103544. Epub 2021 Aug 19.
10
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.三种原型株衍生重组蛋白疫苗对 B.1.1.7、B.1.351 和 B.1.617.1 变异 SARS-CoV-2 诱导产生广谱中和抗体。
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.

引用本文的文献

1
Development and in vivo evaluation of a SARS-CoV-2 inactivated vaccine using high hydrostatic pressure.使用高静水压的新型冠状病毒2型灭活疫苗的研发及体内评价
NPJ Vaccines. 2025 Apr 25;10(1):83. doi: 10.1038/s41541-025-01136-7.
2
VIPERA: Viral Intra-Patient Evolution Reporting and Analysis.VIPERA:病毒患者内进化报告与分析
Virus Evol. 2024 Mar 6;10(1):veae018. doi: 10.1093/ve/veae018. eCollection 2024.
3
Viral Population Heterogeneity and Fluctuating Mutational Pattern during a Persistent SARS-CoV-2 Infection in an Immunocompromised Patient.

本文引用的文献

1
Quantitative epitope analysis reveals drastic 63% reduced immuno-affinity and 60% enhanced transmissibility for SARS-CoV-2 variants.定量表位分析显示,新冠病毒变体的免疫亲和力大幅降低63%,传播性增强60%。
Nanoscale Adv. 2021 Sep 23;3(24):6903-6911. doi: 10.1039/d1na00554e. eCollection 2021 Dec 7.
2
Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination.新出现的严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变异株可逃避感染和疫苗接种所引发的体液免疫反应。
Sci Adv. 2021 Sep 3;7(36):eabj5365. doi: 10.1126/sciadv.abj5365.
3
Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
免疫功能低下患者持续性 SARS-CoV-2 感染期间的病毒群体异质性和突变模式波动。
Viruses. 2023 Jan 19;15(2):291. doi: 10.3390/v15020291.
4
Omicron Sub-Lineage BA.5 and Recombinant XBB Evasion from Antibody Neutralisation in BNT162b2 Vaccine Recipients.BNT162b2疫苗接种者中奥密克戎亚谱系BA.5和重组XBB对抗体中和的逃逸情况
Microorganisms. 2023 Jan 12;11(1):191. doi: 10.3390/microorganisms11010191.
免疫功能低下宿主接受恢复期血浆治疗后出现多种 SARS-CoV-2 抗体逃逸变异体。
mSphere. 2021 Aug 25;6(4):e0048021. doi: 10.1128/mSphere.00480-21.
4
Long-Term Evolution of SARS-CoV-2 in an Immunocompromised Patient with Non-Hodgkin Lymphoma.SARS-CoV-2 在患有非霍奇金淋巴瘤的免疫功能低下患者中的长期进化。
mSphere. 2021 Aug 25;6(4):e0024421. doi: 10.1128/mSphere.00244-21. Epub 2021 Jul 28.
5
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany.在德国接受巴瑞替尼治疗的新冠病毒感染免疫功能低下患者中出现E484K突变
Lancet Reg Health Eur. 2021 Sep;8:100164. doi: 10.1016/j.lanepe.2021.100164. Epub 2021 Jul 14.
6
Immune Evasion of SARS-CoV-2 Emerging Variants: What Have We Learnt So Far?SARS-CoV-2 新兴变异株的免疫逃逸:我们迄今了解多少?
Viruses. 2021 Jun 22;13(7):1192. doi: 10.3390/v13071192.
7
Mild Symptomatic SARS-CoV-2 P.1 (B.1.1.28) Infection in a Fully Vaccinated 83-Year-Old Man.一名83岁完全接种疫苗男子感染轻度症状性SARS-CoV-2 P.1(B.1.1.28)毒株
Pathogens. 2021 May 17;10(5):614. doi: 10.3390/pathogens10050614.
8
SARS-CoV-2 genomic surveillance identifies naturally occurring truncation of ORF7a that limits immune suppression.SARS-CoV-2 基因组监测发现 ORF7a 自然发生的截断,限制了免疫抑制。
Cell Rep. 2021 Jun 1;35(9):109197. doi: 10.1016/j.celrep.2021.109197. Epub 2021 May 14.
9
Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient.巴瑞替尼治疗导致一名感染B.1.1.7且免疫抑制的患者快速筛选出携带E484K突变的免疫逃逸变体。
Clin Infect Dis. 2021 Dec 6;73(11):2144-2145. doi: 10.1093/cid/ciab392.
10
Increased viral variants in children and young adults with impaired humoral immunity and persistent SARS-CoV-2 infection: A consecutive case series.在体液免疫受损且持续 SARS-CoV-2 感染的儿童和年轻成年人中,病毒变异增加:一项连续病例系列研究。
EBioMedicine. 2021 May;67:103355. doi: 10.1016/j.ebiom.2021.103355. Epub 2021 Apr 26.